

Amendment to Share Consolidation Timetable

Sydney, New South Wales, 23 December 2025 – The directors of Invictus Therapeutics Ltd (**Invictus**) (formerly VGI Health Technology Limited (NSX:VTL)) refer to the Company's announcement of 28 November 2025 regarding the timetable for the share consolidation which was approved by Shareholders at the 2025 Annual General Meeting held on 28 November 2025.

Due to unforeseen delays in the administrative process, the Completion Date has been delayed. All other dates remain the same.

The known dates are as follows:

Date	Event
Friday 28 November 2025	Meeting to approve the Consolidation and issue Shares pursuant to Resolutions 2, 3 and 4
Friday 28 November 2025 (Day 0)	Announcement about Consolidation
Thursday 18 December 2025 (Day 10)	Ex-Date
Friday 19 December 2025 (Day 11)	Record Date
To be advised	Completion and dispatch of holding statements

As soon as the date for the dispatch of holding statements has been confirmed, a further announcement will be released.

This announcement was authorised for release by the Managing Director.

For more information please contact:

About Invictus Therapeutics Ltd

Invictus Therapeutics Ltd (formerly VGI Health Technology Limited (NSX:VTL)) is an Australian public listed biotechnology company developing and commercialising prescription medicines and novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD), Metabolic dysfunction-Associated Steatohepatitis (MASH), pancreatic adenocarcinoma (pancreatic cancer), hyperlipidaemia, hypertension and diabetes. Invictus owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a clinical development program for prescription medicines and a product development program for evidence-based nutraceuticals.



Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200